Transfection Reagents & Equipment Market Size, Share & Trends Analysis Report By Method (Electroporation, Adenoviral Vectors), By Application (Transgenic Models), By Region, And Segment Forecasts, 2020 - 2025

Report Overview

The global transfection reagents & equipment market size was valued at USD 871.9 million in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 7.7% from 2020 to 2025. Developments in the field of recombinant technology and proteomics coupled with rising application of transfection procedures by academic researchers are key factors set to propel the growth of the market for transfection reagents and equipment. Ongoing advancements pertaining to the development of novel techniques for transient and stable transfection with minimal off-target effects has attracted various market players to invest in the development of novel products. In August 2017, the Ohio State University Wexner Medical Center along with the Ohio State College of Engineering developed a TNT technology capable of healing tissues and rejuvenating aging cells. Researchers at Ohio State University used TNT to treat car crash victims or injured soldiers. The integration of nanotechnology with transfection is one of the major factors driving the market for transfection reagents and equipment.

The delivery of plasmid DNA or siRNA in insect and mammalian cells has become routine in the experimental workflow of research laboratories. This has propelled manufacturers to launch varied novel reagents and systems that can perform efficient transfection in any type of cell. In the past few years, there has been a significant increase in the number of commercially available reagents and equipment targeted toward large-scale transient transfection of suspension cell lines cultured in chemically defined media.

Several drug patents are expected to lapse in the coming years, which accelerates the development of biosimilar drugs. Their development is significantly dependent on a combination of cytological, genomic, and proteomic analysis. This has resulted in expanding applications of transfection reagents and equipment in proteomic and genomic research.

A growing number of cancer research projects targeted at cancer management are expected to drive the market for transfection reagents and equipment over the forecast period. R&D for cancer management observes the heavy incorporation of transfection methods for the development of stem cell therapy and gene-based therapy.

For instance, Nucleofector technology provided by Lonza and FuGENE HD Transfection by Promega Corporation assists in the successful transfection of cancer cell lines with high efficiency. Similarly, nano-electro-injection has been developed by researchers at the National University of Singapore in October 2019 to ensure the efficient delivery of DNA.

Product Insights

Among the product type, the reagents segment dominated the transfection reagents and equipment market and accounted for the largest revenue share of 53.3% in 2019. The segment is expected to maintain its dominance throughout the forecast period. This can be attributed to a large number of launches by key players aiming to expand their reagents portfolio. Apart from the routine use of reagents and kits across experimental protocols, companies offering reagents at a comparatively affordable cost are set to drive the segment in the market for transfection reagents and equipment.

Conversely, the equipment segment is anticipated to witness lucrative growth during the forecast period. This is due to the development of cell systems that enable simple and cost-effective transient transfection while maintaining performance efficiency and primary cell compatibility. These systems are being employed on a large scale by researchers for various biotherapeutic and drug development activities.

Method Insights

The electroporation segment accounted for the largest revenue share of more than 20.0% in 2019 in the market for transfection reagents and equipment. The segment is followed closely by liposomal transfection and particle bombardment segments in terms of revenue share. Wide portfolios for a range of electroporation solutions offered by established as well as emerging players are boosting segment growth. Contrastingly, the liposomes segment is anticipated to grow at the fastest rate during the forecast period. Ongoing developments in lipofection to enhance the efficiency of in vivo transfection are likely to boost the demand for liposome-based transfection in the coming years.

Different advantages associated with each of the abovementioned techniques have propelled the adoption of reagents and equipment, further contributing to the overall revenue generated in 2019. For instance, electroporation is suitable for primary cell applications and offers reproducible results; whereas the calcium phosphate method is convenient, rapid, and is suitable for in vivo applications.

Application Insights

The gene expression studies segment accounted for the largest revenue share of 22.3% in 2019 in the market for transfection reagents and equipment. This is owing to the expansion of the genomic data pool and rising emphasis on the translation of genomic information in the clinical workflow. In addition, a substantial number of ongoing research projects that focus on gene expression for the identification of chromosomal anomalies are likely to boost segment growth.

Conversely, biomedical research is estimated to register rapid growth during the forecast period in the market for transfection reagents and equipment. In recent years, the concept of transfection using lentivirus has gained immense attention in biomedical research. The management of mutational analysis and library screening holds potential in the field of biomedical research. Therefore, increasing the need for transfection of an exogenous gene in various cell types and specific plasmids for library screening drives the employments of these reagents and systems in biomedical research.

Regional Insights

North America generated the largest revenue share of around 40.0% in 2019 in the market for transfection reagents and equipment. The region is anticipated to maintain this trend throughout the forecast period. This is attributed to the presence of well-established manufacturers and robust funding to promote R&D on cancer therapeutics, precision medicine, and advanced cytological studies. Further market potential of the region can augment key market participants' revenue in the U.S. market for transfection reagents and equipment.

In Asia Pacific, a growing patient pool and subsequent untapped market potential, along with the growing healthcare expenditure, are expected to create a favorable environment for established international manufacturers looking to expand their business of transfection reagents and equipment. This is also supplemented by active government participation targeted towards promoting the use of cell and gene therapy. For instance, a pioneering forum on cell and gene therapy in the Asia Pacific has organized a collaborative session in November 2019, targeted towards analyzing the potential of the CAR-T industry in this region.

Key Companies & Market Share Insights

Several strategic initiatives including portfolio expansions through novel product launches have been adopted by key players to maintain their presence in the market for transfection reagents and equipment. For instance, in March 2019, Lonza launched an extensive portfolio of unique services called CellBio Services, which are designed to meet the requirements of research applications. These services include transfection services, cell-line expansion, and banking services. Whereas, in May 2018, Thermo Fisher Scientific unveiled its Gibco ExpiSf system, the first-ever chemically defined insect protein expression system. This system integrates Lipofectamine transfection technology, along with Gibco media technology and molecular biology capabilities, to deliver efficient and consistent results. The system uses ExpiFectamine Sf Transfection Reagents for the transfection of DNA from an insect cell. Some of the prominent players in the transfection reagents & equipment market include:

• Thermo Fisher Scientific, Inc.

• Promega Corporation

• Lonza

• QIAGEN

• F. Hoffmann-La Roche Ltd.

• Bio-Rad Laboratories Inc.

• Merck KGaA

• OriGene Technologies Inc.

• MaxCyte, Inc.

• POLYPLUS TRANSFECTION

• Horizon Discovery Ltd.

• PromoCell GmbH.

Transfection Reagents & Equipment Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global transfection reagents & equipment market report on the basis of product, method, application, and region:

• Product Outlook (Revenue, USD Million, 2014 - 2025)

  • Reagents

  • Equipment

• Method Outlook (Revenue, USD Million, 2014 - 2025)

  • Electroporation

  • Liposomes

  • Particle Bombardment

  • Microinjection

  • Adenoviral Vectors

  • Calcium Phosphate

  • DEAE-dextran

  • Magnetic Beads

  • Activated Dendrimers

  • Laserfection

• Application Outlook (Revenue, USD Million, 2014 - 2025)

  • Gene Expression Studies

  • Protein Production

  • Transgenic Models

  • Therapeutic Delivery

  • Cancer Research

  • Biomedical Research

• Regional Outlook (Revenue, USD Million, 2014 - 2025)

  • North America

    • The U.S.

    • Canada

  • Europe

    • The U.K.

    • Germany

  • Asia Pacific

    • Japan

    • China

  • Latin America

    • Brazil

  • MEA

    • South Africa